The Overactive Bladder (OAB) Therapeutics Market is segmented by Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Others), Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder), and Region (North America, Europe, Asia-Pacific, and Rest of the World).
The Overactive Bladder (OAB) Therapeutics Market is segmented by Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Others), Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder), and Region ...
The Overactive Bladder (OAB) Therapeutics Market is estimated to grow from USD 3.6 billion in 2020 to USD 4.3 billion by 2026 at a healthy CAGR of 3.0% during the forecast period.
Overactive bladder (OAB) may be a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency. The common symptoms of OAB include high urinary frequency, urgency, and urinary incontinence. These drugs act by antagonizing cholinergic receptors that provide relief from frequent urination.
Key Players
Key players operating in the Overactive Bladder (OAB) Therapeutics market are-
Growing incidence of diseases, such as Parkinson’s disease, which leads to overactive bladder disorder, and the rising geriatric population, are key factors propelling the market growth. Urinary incontinence generally rises with aging. OAB has a major negative impact on the quality of life and health of the aged population. With the rising burden of OAB, coupled with other urinary diseases, the growth of the overactive bladder treatment market is expected to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceutical companies, are anticipated to offer lucrative growth opportunities.
COVID-19 Impact
The COVID-19 outbreak has moderately affected the Overactive Bladder (OAB) Therapeutics industry. The virus outbreak has turned the lives of people worldwide, with the number of cases increasing rapidly. The COVID-19 crisis has reduced the number of visits to hospitals and postponement of urology to curb the spread of the virus, thus affecting market growth amid the pandemic.
This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.
The market is segmented into the following categories-
By Therapy Type
Anticholinergics
Mirabegron
Neurostimulation
Intravesical Instillation
Others
By Disease Type
Idiopathic Overactive Bladder
Neurogenic Overactive Bladder
By Region
North America
Asia-Pacific
Europe
Rest of the World
Therapy Trends
The overactive bladder (OAB) therapeutics market is classified into anticholinergics, mirabegron, neurostimulation, intravesical installation, and others. The anticholinergics segment held a significant market share in 2020 and is estimated to register a healthy CAGR during the forecast timeline. This is mainly attributed to the high prevalence of overactive bladder. Due to bladder muscle weakness post-pregnancy and menopause, women are more vulnerable to the condition. The growing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period, which bolsters the segment growth.
Regional Analysis
The North American market accounted for a significant share in 2020 and is expected to grow at a substantial CAGR in the following years. This is mainly ascribed to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the rising prevalence of the disease with rising age, and the large presence of major players, the market is likely to boost the market growth. Due to the growing prevalence of bladder over-activity, healthcare expenditure, geriatric population, and awareness about overactive bladder treatments, thereby proliferates the regional market growth.
To know which region offers the best growth opportunities,Register Here
Target Audience
Here is the list of the group of customers that the overactive bladder (OAB) therapeutics market hopes to have the greatest opportunity to convert-
Distributors
Suppliers
Manufacturers
Logistics organizations
Government bodies
Report Features
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.
What deliverables will you get in this report?
Key questions this report answers
Relevant contents in the report
How big is the sales opportunity?
In-depth analysis of the Overactive Bladder (OAB) Therapeutics Market
How lucrative is the future?
Market forecast and trend data and emerging trends
Which regions offer the best sales opportunities?
Global, regional and country level historical data and forecasts
Which are the most attractive market segments?
Market segment analysis and forecast
Which are the top players and their market positioning?
Porter’s five forces analysis, PEST analysis, Life cycle analysis
What are the factors affecting the market?
Drivers & challenges
Will I get the information on my specific requirement?
10% free customization
Research Methodology
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.
Customization Options
With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:
Company Profiling
Detailed profiling of additional market players (up to three players)
SWOT analysis of key players (up to three players)
Competitive Benchmarking
Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.
LOADING
LOADING
×
Please enter your contact details. It will allow our analysts to reach out to you.
Allergan PLC (US), Astellas Pharma Inc. (Japan), Cogentix Medical Inc. (US), Endo International PLC (Ireland), Hisamitsu Pharmaceutical Co. Inc. (Japan), Johnson & Johnson (US), Medtronic PLC (Ireland), Pfizer Inc. (US), Sanofi (France), and Teva Pharmaceutical Industries Limited (Israel) are among the key players in the overactive bladders therapeutics market.
Growing incidence of diseases, such as Parkinson’s disease, which leads to overactive bladder disorder, and rising geriatric population, are key factors propelling the market growth. Urinary incontinence generally rises with aging. OAB has a major negative impact on the quality of life and health of the aged population. With the rising burden of OAB, coupled with other urinary diseases, the growth of the overactive bladder treatment market is expected to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceutical companies, are anticipated to offer lucrative growth opportunities.
